PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.12%
Negative revenue growth while ADI stands at 1.75%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-16.95%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-79.40%
Negative EBIT growth while ADI is at 1.32%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-83.45%
Negative operating income growth while ADI is at 1.32%. Joel Greenblatt would press for urgent turnaround measures.
-66.33%
Negative net income growth while ADI stands at 5.55%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-66.18%
Negative EPS growth while ADI is at 3.51%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-65.67%
Negative diluted EPS growth while ADI is at 3.57%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.50%
Share reduction while ADI is at 1.69%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.49%
Reduced diluted shares while ADI is at 1.61%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
22.98%
Dividend growth above 1.5x ADI's 0.38%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-9.73%
Negative OCF growth while ADI is at 71.41%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-5.99%
Negative FCF growth while ADI is at 101.63%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
103.30%
10Y revenue/share CAGR 1.25-1.5x ADI's 82.47%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
3.27%
5Y revenue/share CAGR under 50% of ADI's 35.63%. Michael Burry would suspect a significant competitive gap or product weakness.
10.62%
3Y revenue/share CAGR at 50-75% of ADI's 18.43%. Martin Whitman would question if the firm lags behind competitor innovations.
113.57%
10Y OCF/share CAGR under 50% of ADI's 529.60%. Michael Burry would worry about a persistent underperformance in cash creation.
-6.01%
Negative 5Y OCF/share CAGR while ADI is at 27.25%. Joel Greenblatt would question the firm’s operational model or cost structure.
20.95%
3Y OCF/share CAGR at 50-75% of ADI's 41.34%. Martin Whitman would suspect weaker recent execution or product competitiveness.
165.64%
Below 50% of ADI's 516.65%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-56.90%
Negative 5Y net income/share CAGR while ADI is 80.43%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-55.02%
Negative 3Y CAGR while ADI is 65.27%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
49.55%
10Y equity/share CAGR at 50-75% of ADI's 71.87%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
35.46%
Below 50% of ADI's 75.60%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
25.81%
Below 50% of ADI's 60.42%. Michael Burry suspects a serious short-term disadvantage in building book value.
856.00%
Dividend/share CAGR of 856.00% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
109.92%
5Y dividend/share CAGR above 1.5x ADI's 62.46%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
76.00%
3Y dividend/share CAGR 1.25-1.5x ADI's 52.59%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
-24.21%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-4.92%
Inventory is declining while ADI stands at 0.53%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.19%
Negative asset growth while ADI invests at 3.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.41%
We have a declining book value while ADI shows 1.68%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.07%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-8.21%
Our R&D shrinks while ADI invests at 0.54%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-5.08%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.